Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1060469 Food Effect Study in Healthy Males
NCT02225626Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of BI 1060469 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point at 6 days, Maximum measured concentration of the analyte in plasma at 6 days and 1 more. Started Sep 2014; status: completed.
02
Drugs
BI 1060469
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02225626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225626.